R&D Insights: How Merck & Co., Inc. and Zoetis Inc. Allocate Funds

Merck vs. Zoetis: R&D Investment Strategies Unveiled

__timestampMerck & Co., Inc.Zoetis Inc.
Wednesday, January 1, 20147180000000396000000
Thursday, January 1, 20156704000000364000000
Friday, January 1, 20167194000000376000000
Sunday, January 1, 20179982000000382000000
Monday, January 1, 20189752000000432000000
Tuesday, January 1, 20199872000000457000000
Wednesday, January 1, 202013397000000463000000
Friday, January 1, 202112245000000508000000
Saturday, January 1, 202213548000000539000000
Sunday, January 1, 202330531000000614000000
Monday, January 1, 2024686000000
Loading chart...

Infusing magic into the data realm

R&D Spending: A Tale of Two Giants

In the ever-evolving pharmaceutical landscape, research and development (R&D) is the lifeblood of innovation. Over the past decade, Merck & Co., Inc. and Zoetis Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Merck's R&D expenses surged by over 300%, peaking at an impressive $30.5 billion in 2023. This reflects Merck's commitment to pioneering breakthroughs in human health. In contrast, Zoetis, a leader in animal health, maintained a steady R&D growth, with a 55% increase over the same period, reaching $614 million in 2023. This strategic allocation underscores Zoetis's focus on sustainable innovation. The data reveals a fascinating narrative of how these industry titans prioritize their R&D investments, shaping the future of health solutions for both humans and animals.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025